Volinanserin (MDL 100907) at doses ranging from 0.008 to 2.0 mg/kg, administered intraperitoneally, significantly reduces d-amphetamine-stimulated locomotor activity, with an ED50 of 0.3 mg/kg. However, it does not notably affect baseline locomotor activity. In rats, it induces atalepsy with an ED50 ranging from 10 to 50 mg/kg, while showing no reduction in apomorphine-induced stereotypies or catalepsy^[1].

When combined with MK-801, Volinanserin (M100907) decreases reinforcers at 1 μg/kg but antagonizes the disruptive effect of MK-801 at doses of 10 and 100 μg/kg in rats via intraperitoneal administration. Additionally, at a dose of 6.25 μg/kg, it enhances the antidepressant-like action of Desipramine and elevates the antidepressant-like effect of Tranylcypromine in rats performing under a DRL 72-s schedule^[2].

Volinanserin (MDL 100907) functions as a potent antagonist at the 5-HT2 receptor, displaying a Ki value of 0.36 nM and exhibiting a 300-fold selectivity for the 5-HT2 receptor over the 5-HT1c receptor, alpha-1, and DA D2 receptors. Its activity includes antipsychotic effects^[1].